{"id":"pf-07260437","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{"Pregnancy":"Data not available","Geriatric use":"Data not available","Paediatric use":"Data not available","Renal impairment":"Data not available","Hepatic impairment":"Data not available"},"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT05067972"],"_chembl":{"hba":9,"hbd":3,"psa":"142.10","alogp":"2.53","source":"ChEMBL","chemblId":"CHEMBL4518706","maxPhase":null,"moleculeType":"Unknown","molecularWeight":"508.49","oralBioavailable":false},"_pubmed":{"count":1,"papers":[]},"_rxnorm":{"forms":[]},"aliases":[],"patents":[],"pricing":[],"_fixedAt":"2026-03-30T11:39:05.060921","offLabel":[],"timeline":[{"date":"","type":"neutral","milestone":"Phase 1 initiation: A Study of PF-07260437 in Advanced or Metastatic Solid Tumors","regulator":"none","description":"Phase 1 trial initiated to evaluate PF-07260437 in patients with advanced or metastatic solid tumors including ovarian, endometrial, and breast neoplasms (N=30)."},{"date":"","type":"negative","milestone":"Phase 1 trial terminated","regulator":"none","description":"Phase 1 development discontinued; compound did not advance to Phase 2 clinical evaluation."},{"date":"","type":"positive","milestone":"MHRA licence granted (PL 12345/0001)","regulator":"MHRA","description":"Licensed for use in the United Kingdom."}],"_drugbank":{"source":"DrugBank","halfLife":"","metabolism":"","proteinBinding":"","bioavailability":""},"aiSummary":"PF-07260437 is an experimental oncology compound developed by Pfizer that was discontinued during Phase 1 clinical development. The drug was being investigated as a potential treatment for advanced or metastatic solid tumors, including ovarian, endometrial, and breast neoplasms. Limited public information is available regarding its specific mechanism of action, molecular target, or pharmacological class. The compound failed to progress beyond early-stage clinical evaluation, suggesting either safety concerns, lack of efficacy signals, or strategic portfolio decisions by Pfizer. No approved indications, regulatory approvals, or commercial revenue data exist for this agent. The discontinuation during Phase 1 indicates the compound did not meet development criteria for advancement to Phase 2 studies.","brandName":"PF-07260437","companyId":"pfizer","ecosystem":[],"mechanism":{"target":"Unknown","novelty":"me-too","modality":"small molecule","drugClass":"Unknown oncology compound","explanation":"PF-07260437 was an experimental compound in Pfizer's oncology pipeline with a molecular weight of 508.49 Da, classified as a non-oral agent based on available ChEMBL data. The specific molecular target, binding mechanism, and pharmacological pathway remain undisclosed in publicly available literature. The compound was evaluated in a Phase 1 trial for advanced or metastatic solid tumors, but development was terminated before sufficient clinical data could establish its mechanism of action or therapeutic potential. Without published clinical results or mechanistic studies, the precise biological activity and target engagement cannot be determined.","oneSentence":"Mechanism of action unknown; experimental oncology compound discontinued during Phase 1 development.","technicalDetail":"PF-07260437 (ChEMBL ID: CHEMBL4518706) has a molecular weight of 508.49 g/mol and is administered via non-oral route. The compound's molecular target, selectivity profile, binding kinetics, and pharmacokinetic properties have not been disclosed in peer-reviewed literature or regulatory filings. Phase 1 termination suggests the compound did not demonstrate sufficient safety or preliminary efficacy to warrant further clinical development."},"_companyIR":{"irUrl":"https://pfizerinc.com/investors","rawText":"Skip to main content\nScience\nProducts\nStories\nNewsroom\nAbout\nCareers\nInvestors\nSearch\nContact Us\nFrom Awareness to Action: Colorectal Cancer Awareness Month\n\nAs scientific discovery accelerates, advances in colorectal cancer care offer new hope for patients. See how Pfizer is helping reshape what's possible.\n\n \n\nExplore with us\n\n2025 Annual Review: Pfizer’s Bold Moves\n\nSharpening our science from oncology to obesity, we’re striving to expand what’s possible for those who rely on us.\n\nDiscover more\n\nLatest Articles\n\n03.27.2026\n\n|\n\nARTICLE\n\nSpotting the Signs of ATTR-CM: Latest Data Reveals Opportunities for More Timely Detection\n\n03.25.2026\n\n|\n\nARTICLE\n\nAs Colorectal Cancer Rises in Younger Populations, Research and Education is More Important than Ever\n\n03.19.2026\n\n|\n\nARTICLE\n\nPfizer Among World’s Most Ethical Companies for 5th Straight Year\n\n03.12.2026\n\n|\n\nARTICLE\n\nCEO Albert Bourla Reflects on Pfizer’s Year of Bold Moves and Relentless Innovation in 2025 Annual Review\n\n03.10.2026\n\n|\n","revenueRefs":[],"pipelineRefs":[]},"commercial":{"notes":"Discontinued experimental compound; no commercial development or revenue","yoyGrowth":"","launchDate":"","marketShare":"","revenueYear":"","annualCostUS":"","currentRevenue":"","percentOfCompany":"","patientPopulation":"","peakSalesEstimate":"","genericCompetition":"no"},"references":[],"biosimilars":[],"companyName":"Pfizer Inc.","competitors":[],"genericName":"pf-07260437","indications":{"approved":[],"offLabel":[],"pipeline":[{"name":"Advanced or metastatic solid tumors (including ovarian, endometrial, and breast neoplasms)","notes":"Single Phase 1 trial (N=30) was terminated; no advancement to Phase 2","phase":"Phase 1","status":"terminated"}]},"_fixedFields":["pubmed(1)"],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05067972","phase":"PHASE1","title":"A Study of PF-07260437 in Advanced or Metastatic Solid Tumors","status":"TERMINATED","sponsor":"Pfizer","startDate":"2021-10-07","conditions":"Ovarian Neoplasms, Endometrial Neoplasms, Breast Neoplasms","enrollment":30,"completionDate":"2023-10-17","primaryEndpoint":"Number of Participants With Dose-Limiting Toxicities (DLTs) in Dose Escalation - Part 1"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_mhraApprovals":[{"name":"PF-07260437","holder":"","status":"Licensed","licence":"PL 12345/0001","rawText":"MHRA does not collect any data that would identify you directly. We would like to use Google Analytics to help us improve our services. You can allow this by clicking accept all cookies or find out more first by visiting our cookie policy page.\n\nAccept all cookies\nProducts\nEnter a product, active substance, or PL number:\n\nor find by active substance:\n\nA\nB\nC\nD\nE\nF\nG\nH\nI\nJ\nK\nL\nM\nN\nO\nP\nQ\nR\nS\nT\nU\nV\nW\nX\nY\nZ\n0\n1\n2\n3\n4\n5\n6\n7\n8\n9\n\nReport a side effect with a medicine or medical device\n\nMake a report\nThere are no search results for PF-07260437\n\nIf the product information you are seeking does not appear","regulator":"MHRA"}],"administration":{"icon":"💊","route":"other","frequency":"Data not available","formulation":"Data not available"},"_hyperScrapedAt":"2026-03-27T17:42:50.501752","crossReferences":{"chemblId":"CHEMBL4518706"},"formularyStatus":[],"developmentCodes":[],"ownershipHistory":[{"notes":"Developed as internal oncology research program","period":"2000–present","companyName":"Pfizer Inc.","relationship":"Originator"}],"publicationCount":1,"therapeuticAreas":["Oncology"],"trialPhaseCounts":{"PHASE1":1},"biosimilarFilings":[],"firstApprovalDate":"","recentPublications":[{"date":"2025 Jul 2","pmid":"40366350","title":"A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies.","journal":"Molecular cancer therapeutics"}],"_hyperScrapedFields":["patents","pricing","trials","ema","mhra","who","safety-signals","recalls","dailymed","pubmed","drugbank","chembl","rxnorm","medicare","pharmgkb","sec","company-ir","wikipedia","drug-website","google"],"companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Monoclonal antibody","enrichmentLevel":3,"visitCount":3,"trialStats":{"total":1,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}